Jamie Lujan
Family · Las Cruces, NMNPI 1356985428
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Boehringer Ingelheim accounts for 65.8% of it on its own, with 23 other manufacturers making up the rest. 2025 is the largest year on record at $6,883, more than ten times the $441 reported in 2021. Among family clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 290 payments — averaging $47.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$9K
- GSK$1K
- AstraZeneca$927
- Grifols USA, LLC$386
- Regeneron Healthcare Solutions, Inc.$360
- Mylan Specialty L.p.$332
- plus $2K from 18 others
What the payments were for
- Speaking & faculty fees$5,88042%
- Travel & lodging$1,68912%
- Food & beverage$6,10744%
- Education$1761%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 52 | $9,115 |
| GSK | 73 | $1,093 |
| AstraZeneca | 37 | $927 |
| Grifols USA, LLC | 22 | $386 |
| Regeneron Healthcare Solutions, Inc. | 17 | $360 |
| Mylan Specialty L.p. | 18 | $332 |
| Sanofi | 15 | $291 |
| United Therapeutics Corporation | 5 | $268 |
| Actelion Pharmaceuticals US, Inc. | 9 | $182 |
| Viatris Specialty LLC | 7 | $149 |
| Verona Pharma, Inc. | 4 | $97 |
| Novartis | 5 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $79 |
| Philips North America LLC | 5 | $78 |
| Sanofi-aventis U.S. LLC | 1 | $75 |
| Baxter Healthcare | 3 | $66 |
| Abiomed | 1 | $62 |
| Insmed, Inc. | 3 | $49 |
| AbbVie | 2 | $44 |
| Merck | 2 | $40 |
| Electromed, Inc. | 1 | $23 |
| Inogen, Inc. | 2 | $20 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| Bayer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,852 in reported general payments places this provider in the 95th percentile of 1,080 family providers in New Mexico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 113 | $1,367,312 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 631 | $565,345 |
| Spiriva RespimatTiotropium Bromide | 333 | $311,089 |
| NucalaMepolizumab | 61 | $260,606 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 301 | $249,464 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 228 | $222,447 |
| Bosentan | 19 | $188,955 |
| Dupixent PenDupilumab | 39 | $167,936 |
| Pirfenidone | 27 | $142,798 |
| SymbicortBudesonide/Formoterol Fumarate | 339 | $131,205 |
| Breo ElliptaFluticasone/Vilanterol | 156 | $98,618 |
| Orenitram ErTreprostinil Diolamine | 17 | $97,014 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 122 | $86,277 |
| XolairOmalizumab | 19 | $56,625 |
| Arnuity ElliptaFluticasone Furoate | 135 | $44,711 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $9,115 | $1,972,082800 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,093 | $1,087,9221,182 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere, Airsupra | $927 | $372,175598 claims |
| Actelion Pharmaceuticals US, Inc.Bosentan | $182 | $188,95519 claims |
| MerckDulera | $40 | $31,35971 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,080 family providers in New Mexico.
Other family in Las Cruces
- Joleen LeszczynskiLas Cruces$8K
- Deborah PachecoLas Cruces$6K
- Angelina CarverLas Cruces$5K
- Russell CoryellLas Cruces$5K
- Jessica AltamiranoLas Cruces$5K
- Laura OrtegaLas Cruces$4K
- Rachel SaavedraLas Cruces$3K
- Thomas HaythLas Cruces$3K
- David SeiterFarmington$194K
- Carol HollandRoswell$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.